Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome
https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr https://clinicaltrials.gov/ct2/show/NCT04496960?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=07%2F21%2F2020&lupd_d=14&sort=nwst STUDY TITLE: Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren’s Syndrome Phase Ib-IIa Placebo-Controlled Clinical Trial and Associated Mechanistic Studies DESCRIPTION: Condition: Sjogren’s SyndromeInterventions: Drug: tofacitinib; Other: PlaceboSponsor: National Institute of Dental and Craniofacial Research (NIDCR)Not yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04496960 FIRST POSTED: Tue, 04 Aug 2020 12:00:00 EDT […]
Fecal Microbial Transplant (FMT) for Sjogren’s Syndrome [Completed]
https://www.clinicaltrials.gov/ct2/show/NCT03926286?type=Intr&cond=Sjogren%27s+Syndrome&sort=nwst&draw=2&rank=9 Fecal Microbial Transplant (FMT) for Sjogrens Syndrome Study Description Go to sections Brief Summary: This is an open label study to evaluate the effect of Fecal Microbiota Transplantation (FMT) on the gut microbiome and Systemic parameters. Condition or disease Intervention/treatment Phase Sjogren’s Syndrome Drug: FMP-30 Phase 1 Study Design Go to sections Study Type […]
Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome
https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst STUDY TITLE: Pilot Trial of Ustekinumab for Primary Sjögren’s Syndrome DESCRIPTION: Condition: Primary Sjögren SyndromeIntervention: Drug: UstekinumabSponsor: University of RochesterNot yet recruiting CLINICALTRIALS.GOV IDENTIFIER: NCT04093531 FIRST POSTED: Wed, 18 Sep 2019 12:00:00 EDT LAST UPDATE POSTED: 10/22/19 07:00AM STUDY LINK / URL: https://clinicaltrials.gov/ct2/show/NCT04093531?type=Intr&cond=Sjogren%27s+Syndrome&lupd_s=10%2F08%2F2019&lupd_d=14&sort=nwst
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren’s Syndrome
https://www.clinicaltrials.gov/ct2/show/NCT04078386 A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren’s Syndrome